KL-11743 is an orally available, potent inhibitor of class I glucose transporters that blocks glucose uptake in vitro and in vivo. It induces aspartate accumulation and increases mitochondrial metabolism. KL-11743 specifically inhibits the growth of tumors containing truncated the tricarboxylic acid (TCA) cycle due to mutations inactivating succinate dehydrogenase. Inhibition of glucose uptake by KL-11743 may synergize with therapies that induce oxidative stress (synthetic lethality).
orally available, potent inhibitor of class I glucose transporters that blocks glucose uptake in vitro and in vivo